HC Wainwright Forecasts Increased Earnings for Vor Biopharma

Vor Biopharma Inc. (NASDAQ:VOR) – Stock analysts at HC Wainwright boosted their Q4 2026 earnings per share estimates for shares of Vor Biopharma in a research note issued to investors on Monday, November 2nd. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings per share of ($0.83) for the quarter, up from their prior forecast of ($0.94). The consensus estimate for Vor Biopharma’s current full-year earnings is ($2.56) per share. HC Wainwright also issued estimates for Vor Biopharma’s Q1 2027 earnings at ($0.84) EPS, Q2 2027 earnings at ($0.86) EPS, Q3 2027 earnings at ($0.78) EPS, Q4 2027 earnings at ($0.79) EPS, FY2027 earnings at ($3.26) EPS, FY2028 earnings at ($2.10) EPS, FY2029 earnings at $1.50 EPS and FY2030 earnings at $3.90 EPS.

Vor Biopharma (NASDAQ:VOR) last released its earnings results on Friday, October 30th. The company reported ($1.45) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.81) by ($0.64).

Several other equities analysts have also commented on VOR. Citigroup raised shares of Vor Biopharma to a “strong-buy” rating in a report on Thursday, October 15th. Stifel Nicolaus set a $40.00 price objective on Vor Biopharma in a research note on Monday. William Blair began coverage on Vor Biopharma in a report on Wednesday, October 21st. They set an “outperform” rating on the stock. Wedbush lifted their target price on shares of Vor Biopharma from $18.00 to $27.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 12th. Finally, Weiss Ratings raised Vor Biopharma from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday, September 14th. Two research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $38.29.

Vor Biopharma Stock Performance

Shares of NASDAQ VOR opened at $19.86 on Wednesday. Vor Biopharma has a 52 week low of $6.50 and a 52 week high of $26.00. The stock’s fifty day moving average is $20.61 and its 200 day moving average is $17.39.

Institutional Trading of Vor Biopharma

Several large investors have recently modified their holdings of the stock. Parallel Advisors LLC increased its stake in shares of Vor Biopharma by 29,640.0% in the 3rd quarter. Parallel Advisors LLC now owns 1,487 shares of the company’s stock valued at $28,000 after acquiring an additional 1,482 shares in the last quarter. Alps Advisors Inc. boosted its stake in Vor Biopharma by 42.5% during the third quarter. Alps Advisors Inc. now owns 78,371 shares of the company’s stock worth $1,495,000 after acquiring an additional 23,373 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new position in Vor Biopharma during the third quarter worth $58,000. China Universal Asset Management Co. Ltd. grew its holdings in Vor Biopharma by 25.2% in the third quarter. China Universal Asset Management Co. Ltd. now owns 10,795 shares of the company’s stock worth $198,000 after purchasing an additional 2,171 shares during the period. Finally, Engineers Gate Manager LP grew its holdings in Vor Biopharma by 37.5% in the second quarter. Engineers Gate Manager LP now owns 36,951 shares of the company’s stock worth $680,000 after purchasing an additional 10,071 shares during the period. Institutional investors and hedge funds own 97.29% of the company’s stock.

About Vor Biopharma

Vor Biopharma Inc is a clinical-stage biotechnology company focused on developing engineered hematopoietic stem cell therapies for the treatment of cancer, particularly blood cancers. The company combines gene-editing technologies with targeted immunotherapies to address limitations associated with conventional cancer treatments.

Vor’s platform is designed to create engineered hematopoietic stem cells that can protect healthy blood-forming cells from targeted therapies. Its lead program, VOR33, is an investigational CD33-edited hematopoietic stem cell therapy intended to support the use of CD33-targeted treatments in patients with acute myeloid leukemia.